OKYO Pharma Ltd Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by OKYO Pharma Ltd on May 19, 2026. The report serves to announce a corporate governance update regarding the expansion of the Company's Scientific Advisory Board (SAB).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
The primary material change disclosed is the appointment of Marta Sacchetti, MD, PhD, to the Scientific Advisory Board. This action is intended to enhance the Company's global scientific network with premier European specialists.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies. The document focuses solely on the strategic appointment.
Key Facts for Investor Verification
- Confirmation of Marta Sacchetti's credentials and prior experience in European pharmaceuticals.
- Details regarding the specific therapeutic areas or projects the new SAB member will advise on.
- Any potential compensation arrangements or conflicts of interest associated with the appointment.
- Impact of this appointment on the Company's upcoming clinical trial timelines or regulatory strategy.